Sartar Therapeutics
Therapeutics & Diagnostics · Helsinki
Precision drug for rare soft-tissue sarcomas (GIST, liposarcoma): SAR001 = reformulated depot anagrelide targeting PDE3A overexpressed in sarcomas. Preclinical.
Pre-revenue📍 Helsinki📅 Founded 2016🎓 Univ. of Helsinki
The row
- Stage
- Pre-revenue — No sales yet
- Location
- Helsinki
- Founded
- 2016
- Research origin
- Univ. of Helsinki
- Business ID
- 2754654-8 · Finnish trade register
- Funding
- ~$2.7M total (incl. a €2.3M seed in 2020)
Links
Where this sits on the map
Sartar Therapeutics is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗